Pricing, Value, And Access To CGTs With The Dedham Group's Jennifer Klarer, M.Sc. Eng.
The Dedham Group's Jennifer Klarer, M.Sc. Eng., joins Erin Harris on this episode of Cell & Gene: The Podcast for a deep dive into pricing and value of CGTs. Klarer shares a detailed breakdown of the most misunderstood aspects of cell and gene therapy pricing, value, and affordability. She details how manufacturers can get ahead of addressing time to treatment issues typically experienced at launch. Listen now to their discussion about obtaining adequate investment dollars.
Insights gleaned from a variety of animal species, and a deeper understanding of evolution aided by artificial intelligence, could help bring a new wave of therapies to market.
The landscape of neurological and rare disorders is as diverse as the human population it affects. Yet, clinical trials for these conditions have not always mirrored this diversity.
The FDA Race And Ethnicity Diversity Plan
Understand how the DEPICT Act not only underscores the importance of diversity in research but also sets the stage for a more inclusive and comprehensive approach to healthcare development in the U.S.
CONTRIBUTE TO LIFE SCIENCE LEADER
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
|Connect With Life Science Leader: